Please ensure Javascript is enabled for purposes of website accessibility

Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

By Mark Prvulovic - Feb 27, 2020 at 8:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The partnership would focus on developing treatments for neurological diseases.

Sangamo Therapeutics (SGMO 3.50%) announced after the bell on Thursday that it signed a partnership with Biogen (BIIB 3.40%) to develop a number of gene-editing treatments. The scope of the agreement would focus on neurological and neuromuscular conditions, with an initial focus on treating Alzheimer's and Parkinson's diseases.

Sangamo currently has 17 separate preclinical or early-stage clinical projects going on at the moment. One of these, ST-501, targets a class of neurodegenerative disorders known as tauopathies, which include conditions such as Parkinson's disease. Another candidate Sangamo is working on, ST-502, treats another class of neurodegenerative disorders known as synucleinopathies, which includes Alzheimer's disease.

Four laboratory scientists shaking hands in a lab.

Image source: Getty Images.

Under this new deal, Biogen would have exclusive global rights to market ST-501 and ST-502. The announcement also mentioned a third undisclosed neuromuscular disease that the two biotech companies are targeting, although it's anyone's guess at this point as to which condition it could be.

A major deal for both parties

The agreement stipulates that Biogen will pay Sangamo $350 million immediately, and Sangamo is eligible to receive up to $2.4 billion in milestone payments should its drug candidates prove successful.

Although Sangamo has a relatively large clinical pipeline in comparison to other gene-editing companies, most of them are still in preclinical stages of development. Only five of the 17 drug projects listed on Sangamo's website have entered early, phase 1/2 clinical trials. Most notable of these are its sickle cell disease and transfusion-dependent beta-thalassemia drugs, BIVV003 and ST-400, as well as the Fabray disease drug ST-920 and a hemophilia A treatment called SB-525.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sangamo Therapeutics Stock Quote
Sangamo Therapeutics
$4.14 (3.50%) $0.14
Biogen Inc. Stock Quote
Biogen Inc.
$199.65 (3.40%) $6.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.